Rationale: Stroke is the third most common cause of death in industrialized countries. The main therapeutic target is the ischemic penumbra, potentially salvageable brain tissue that dies within the first few hours after blood flow cessation. Hence, strategies to keep the penumbra alive until reperfusion occurs are needed.
of ischemic brain damage is thrombolysis by local or systemic administration of recombinant tissue plasminogen activator (rtPA). A major drawback of rtPA, however, is that it may be fatal if administered in patients with hemorrhagic stroke who present with similar symptoms as ischemic stroke patients. Before hemorrhagic stroke, however, can be ruled out by advanced imaging techniques, the therapeutic window for rtPA, recently extended from 3 to 4.5 hours after the onset of ischemia, 5 has often closed. As a result, less than 5% of all stroke patients are eligible for rtPA thrombolysis according to current protocols. The remaining 95% may only hope for spontaneous reperfusion, which in most cases occurs too late to prevent penumbral cell death and, hence, fails to restore neurological function. 6 Accordingly, novel strategies are required to prolong neuronal survival in the ischemic penumbra.
Nitric oxide (NO), a potent endogenous vasodilator, was originally proposed to have an exclusively pulmonary effect when given by inhalation. Whereas few studies saw mild hypotension 7, 8 under NO inhalation, a significant decrease of systemic blood pressure was only detected under high NO concentrations (300 ppm). 8 Most experimental and clinical studies, however, did not detect any changes in systemic blood pressure or other disadvantageous side effects. Based on this notion, inhaled NO (iNO) was approved to treat diseases caused by pulmonary vasoconstriction, eg, persistent pulmonary hypertension of the newborn. In contrast to the proposed pulmonary selectivity of iNO, we have previously demonstrated that iNO increases cerebral blood volume without influencing cerebral blood flow (CBF) in healthy pigs. 9 Accordingly, we hypothesized that iNO may have a previously unnoticed direct effect on the cerebral vasculature.
In the present study, we therefore investigated the effect of iNO on the cerebral microcirculation by in vivo fluorescence microscopy. Because our results indicated that iNO preferentially dilates arterioles in areas of low perfusion, we hypothesized that iNO may serve as a specific vasodilator of collateral vessels in the ischemic penumbra after experimental stroke. Therefore, we analyzed the effects of iNO on CBF, cerebral metabolism, neuronal cell death, and functional outcome in murine models of cerebral ischemia and validated these findings in a clinically relevant large animal model of ischemic stroke in sheep. week-old to 10-week-old C57BL/6 mice (25-30 g) (provided by Charles River Laboratories, Kisslegg, Germany) were anesthetized, intubated, and mechanically ventilated as previously described. 10 Anesthesia for all intravital microscopy experiments was induced by intraperitoneal injection of medetomidine, midazolam, and fentanyl.
Methods Animals

Transient and Permanent Focal Cerebral Ischemia: Chronic Experiments (24 Hours/12 Hours/7 Days)
Experimental middle cerebral artery (MCA) occlusion was induced under 1.2% isoflurane in 70% N 2 O and 30% O 2 administered by a face mask.
Perinatal Hypoxia
Pups were anesthetized with isoflurane (1.0%-1.5%) in a 50%/50% mixture of N 2 O and O 2 via facemask.
Permanent Focal Ischemia in Sheep
Adult female merino sheep were anesthetized as outlined previously. 11 Blood gas analysis was performed using a standard clinical analyzer with samples obtained from the tarsal/metatarsal artery.
Inhalation of NO
NO (268 mg/m 3 N 2 ) was mixed with oxygen and room air to obtain final concentrations of 5 to 50 ppm NO in 30% O 2 . NO 2 was Ͻ1.2 mm Hg at all times. Controls received 30% oxygen. For long-term inhalation, mice were kept in temperature-controlled gas-proof cages with inlet and outlet valves under continuous monitoring of oxygen, NO, and N 2 O concentrations. N 2 O concentration was Ͻ1.2 ppm at all times.
Cerebral Hypoperfusion
Both common carotid arteries were occluded until CBF was reduced to 30% to 40% of baseline as assessed by laser Doppler fluxmetry. 12 Transient and permanent focal cerebral ischemia. Mice were subjected to transient MCA occlusion by an intraluminal filament as previously described. 13 For transient ischemia, the filament was removed after 45 minutes and mice were euthanized after 24 hours of reperfusion. For permanent ischemia, the filament was left in place until the end of the experiment 12 hours after MCA occlusion.
Perinatal Hypoxic-Ischemic Injury
The 9-day-old C57/BL6 male mouse pups were exposed to hypoxicischemic injury as previously described. 14 One hour after ligature of the left common carotid artery, pups were subjected to hypoxia for 50 minutes with or without addition of NO to the gas mixture (50 ppm). After 72 hours brains were removed, 5-m paraffin coronal sections were prepared for quantification of brain injury by MAP 2 staining. 14 Brain injury was then evaluated. A pathological score (0 -22) was determined for different brain regions. 14 
CBF Measurement in Mice
Regional CBF was measured through the intact skull by laser Doppler fluxmetry as previously described. 13 In mice subjected to MCA occlusion, regional CBF was determined in the ischemic core region (regional CBF Ͻ20% of baseline), the penumbra (regional CBF 25%-40% of baseline), or the surrounding normal cortex (regional CBF Ͼ80% of baseline).
Intravital Microscopy
Intravital fluorescence microscopy of brain microvessels was performed as previously described. 15 A cranial window was prepared over the MCA territory and pial microvessels were visualized by intravenous injection of FITC-dextran. The diameters of at least two arterioles venules were analyzed. Intact vasoreactivity was confirmed at the end of each experiment by CO 2 -induced vasodilation. 
Non-standard Abbreviations and Acronyms
Inhibition of Soluble Guanylyl Cyclase
Topically, 1H- [1, 2, 4] Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) was used at a final concentration of 10 mol/L 16 after careful mechanical permeabilization of the dura mater using a custom-made micropin.
NO Imaging
In vivo NO imaging was performed by adaptation of our previously reported in situ technique, 17 ie, the cortex was superfused with the NO-sensitive dye 4-amino-5-methylamino-2Ј,7Ј-difluorofluorescein (DAF-FM) for 30 minutes after microperforation of the dura mater. DAF-FM fluorescence was imaged at 480 nm.
Measurement of S-Nitroso-Hemoglobin and Nitrite
Concentrations of NO adducts were measured in snap-frozen arterial blood of mice with or without NO inhalation by a previously described chemiluminescence technique. 18
Positron-Emission Tomography
Mice received 14 MBq of 18 
Determination of Bleeding Time
Tail bleeding time after 30 minutes of iNO was determined in mice. A 1-cm segment of the tail was amputated; subsequently, the tail was placed horizontally in saline kept at 37°C. Bleeding time was visually determined and timed.
Determination of Infarct Size by Histomorphometry
Lesion volume was assessed in 12 sequential cryosections. Infarct volumes were normalized to the contralateral hemisphere.
Permanent MCA Occlusion in Sheep
Adult female merino sheep (bred at Leipzig University Veterinary Faculty Breeding Facility, Leipzig, Germany) were subjected to permanent distal middle cerebral artery occlusion as described previously. 11 Baseline PET imaging was performed afterward. Two hours after induction of ischemia, one group of animals received 50 ppm of iNO for 60 minutes, whereas controls were ventilated normally. Animals were then subjected to serial PET scans (tϭ30 minutes, tϭ55 minutes, tϭ90 minutes).
Functional Outcome
Neurological function was assessed by the Neurological Severity Score as previously described. 19 Mice that did not survive until the end of the observation period received the worst score achieved by an animal of their respective group on the respective day. Body weight was recorded as a parameter of general well-being.
Statistical Analysis
All data are given as meansϮSEM. Repeated measurements in one animal were analyzed by the Friedman test. Independent groups were compared by the Mann-Whitney rank-sum test. Statistical significance was assumed at PϽ0.05. All calculations were performed with a standard statistical software package (Sigma Stat 3.0; Jandel Scientific).
Results
Cerebrovascular Effects of NO Inhalation in Normally Perfused Brain
In the first series of experiments, we investigated whether iNO exerts cerebrovascular effects in healthy brain. In anesthetized mice, we monitored regional CBF by laser Doppler fluximetry and microvascular diameters of pial arterioles and venules by intravital fluorescence microscopy during inhalation of 50 ppm NO. At this concentration, no effects on the systemic circulation or gas exchange were observed (for physiological parameters for all experiments see Online Table I .) and iNO did not alter CBF ( Figure 1A ). Absent effects on cerebral vascular resistance were reflected by unchanged diameters of cerebral arterioles, the major resistance vessels in the brain ( Figure 1B) . In contrast to arterioles, pial venules dilated by 10%Ϯ1% during NO inhalation and gradually returned to baseline diameters after discontinuation of iNO ( Figure 1C , D), thereby demonstrating that iNO does not affect cerebral resistance vessels and, thus, cerebral perfusion. The vasodilatory response in mouse pial venules was dose-dependent within the clinically relevant dose range of iNO in humans (5-50 ppm; Figure 1E ). To investigate whether iNO reaches the brain vasculature and induces cerebral venodilation directly, we blocked cerebral NO signaling by topical application of the soluble guanylyl cyclase blocker ODQ onto the cerebral cortex. ODQ completely inhibited the iNO-induced dilation of pial venules, thereby demonstrating that the response was attributable to local NO effects in the brain (Figure 2A ). To further prove that NO reaches the cerebral microvasculature on NO inhalation, we visualized NO in vivo by molecular fluorescence imaging with the NO-sensitive DAF-FM. DAF does not directly react with NO but detects nitrosonium ions (NO ϩ ), therefore assaying NO oxidation products such as N 2 O 3 and also S-nitrosothiols. In pial venules of healthy mice, DAF-FM fluorescence in the microvascular wall remained stable at baseline but increased during NO inhalation concomitantly with vasodilatation ( Figure 2B ). These data clearly show that under physiological conditions iNO reaches the brain and dilates pial venules directly and not through an indirect pulmonary effect. This implies that bioactive NO most probably needs to be transported from the lung to the brain. To investigate the mechanisms of this putative transport, we measured two proposed NO carriers, nitrite and S-nitroso-hemoglobin, in arterial blood of mice inhaling NO. The concentration of both molecules increased significantly on NO inhalation ( Figure 2C , D), thereby suggesting that bioactive NO is transported from the lung to the brain via the blood stream.
Cerebrovascular Effects of NO Inhalation in Cerebral Ischemia
To investigate why iNO is only released in cerebral venules and dilates only this component of the cerebral vasculature while arterioles remain unaffected, we hypothesized that the selective release of NO in venules was mediated by the different conditions present in arterioles and venules, ie, PO 2 , PCO 2 , or pH. The most straightforward experimental strategy to test this hypothesis was to investigate the vasodilatory effect of iNO under conditions in which arteriolar and venular PO 2 , PCO 2 , and pH gradients become similar, ie, during hypoperfusion. We induced cerebral hypoperfusion by bilateral carotid artery banding. In control mice, reduction of CBF to 30% of baseline decreased diameters of pial arterioles and venules by 10% because of the reduction in volume flow ( Figure 3A, B ; control). As expected, NO inhalation in-creased the diameter of pial venules ( Figure 3A ; iNO). Most interestingly, however, iNO also dilated pial arterioles by 22%Ϯ3.2% ( Figure 3B ; iNO). To investigate if this arteriolar vasodilatation was caused by NO, we visualized endothelial NO by intravital imaging with DAF-FM ( Figure 3C ). Normally perfused pial arterioles did not show any relevant increase in fluorescence on NO inhalation, yet the fluorescence signal increased significantly when iNO was administered during cerebral hypoperfusion ( Figure 3C, D) . These data suggest that iNO is transported from the lung to the brain via the blood stream and is released in cerebral venules by an oxygenation-dependent mechanism. Because during hypoperfusion and ischemia the oxygenation gradient between venules and arterioles assimilates, NO is also released in cerebral resistance vessels under these conditions. Accord-ingly, NO applied by this specific route may serve as a selective arteriolar vasodilator in hypoperfused tissue.
Because most stroke patients have atherosclerosis leading to endothelial dysfunction and impaired cerebrovascular NO production, we tested whether iNO causes arteriolar vasodilatation also under this clinically highly relevant condition. Using a mouse model of atherosclerosis, we demonstrated that iNO dilates atherosclerotic arterioles to the same degree as healthy vessels, suggesting that the therapeutic potential of iNO is not affected by atherosclerosis (Online Figure II) .
Next, we examined whether iNO dilates penumbral venules and arterioles in a well-established mouse model of ischemic stroke (MCA occlusion). NO inhalation induced a marked vasodilatation of pial venules ( Figure 4A ) and arterioles ( Figure 4B ) in the ischemic penumbra. Laser Doppler fluximetry demonstrated that these vasoactive effects resulted in a selective increase of CBF in the ischemic penumbra, whereas perfusion of the surrounding normal cortex and the central necrotic infarct core remained unchanged ( Figure 4C ). Measurement of absolute CBF by [ 14 C]iodoantipyrine autoradiography verified this finding (Online Figure IIIA, B) .
The observed approximate 40% increase in penumbral blood flow was associated with a proportionally improved metabolic function in the penumbra, as demonstrated by micro-PET analysis with 18 F-fluorodeoxy-glucose ( Figure  4D , E). In addition, PET analysis revealed that the area of brain tissue deficient of oxidative metabolism was significantly smaller in iNO-treated as compared to control mice ( Figure 4E ), indicating that iNO restores oxidative metabolism in the ischemic penumbra.
Effect of NO Inhalation on Neuronal Cell Damage and Outcome in Ischemic Stroke
To evaluate whether the iNO-induced increase in penumbral blood flow and glucose metabolism attenuates ischemic brain damage, we subjected mice to 45 minutes of MCA occlusion followed by 24 hours of reperfusion and quantified the volume of infarcted tissue on cresyl violet-stained coronal brain sections. No histological evidence for microhemorrhage or macrohemorrhage was observed in control or in NOtreated animals. When NO inhalation (50 ppm) was started 10 minutes and 1 hour after induction of transient cerebral ischemia or 10 minutes after permanent MCA occlusion and maintained for 60 minutes, ischemic tissue injury was markedly attenuated and infarct volume was reduced by Ͼ40% as compared to control mice ( Figure 5A, B) . Because iNO is supposed to improve penumbral blood flow only when applied during ischemia, we performed a control experiment starting iNO treatment 75 minutes after reperfusion, ie, 2 hours after MCA occlusion. Under this condition, as expected, no protective effect was observed ( Figure 5B ; iNO 2 hours).
All experiments performed so far suggest that iNO increases CBF exclusively in the ischemic penumbra, ie, in hypoperfused brain tissue at risk for infarction. If this assumption is correct, then iNO should be able to maintain penumbral viability as long as hypoperfusion persists. To test this hypothesis, we performed permanent MCA occlusion and ventilated mice with 50 ppm NO beginning from 10 minutes after onset of ischemia for a total period of 12 hours (longer occlusion periods were not possible because of ischemia- induced mortality rate Ͼ80% in the control group). Even over this extended ischemic period NO inhalation reduced total infarct volume by almost 40% (Figure 5C ). Thus, NO inhalation appears to prevent ischemic brain tissue damage as long as ischemia persists.
To investigate whether these acute beneficial effects of iNO also translate into long-term neurological improvement, functional outcome was assessed over a period of 7 days after MCA occlusion. Mice treated with iNO (50 ppm) for 24 hours after onset of ischemia performed significantly better in a neurological test battery analyzing motor function, agility, and coordination (PϽ0.01; Figure 5D ). Furthermore, iNOtreated mice recovered significantly better from postischemic weight loss (PϽ0.04; Figure 5E ) and showed a tendency toward improved survival (50% vs 70% mortality, not significant).
Effect of NO Inhalation on Perinatal Hypoxic-Ischemic Brain Damage
To test our hypothesis that iNO is effective in hypoxic regions only and to validate our findings using iNO in experimental stroke in a different model and in a different laboratory, iNO was performed in a well-standardized model of murine perinatal hypoxia-ischemia (unilateral common carotid artery occlusion plus hypoxia). The iNO was also protective in this model. Tissue loss and pathological scores were significantly attenuated by 50 ppm iNO 3 days after the insult (PϽ0.03; Figure 6A , B).
Effect of NO Inhalation in an Ovine Model of Ischemic Stroke
So far, we demonstrated that iNO acts as a selective vasodilator in hypoxic brain tissue, thus improving perfusion of the ischemic penumbra and reducing infarct size in murine models of ischemic stroke. To investigate if iNO is equally effective across species, we tested iNO in a clinically relevant large animal stroke model in sheep. Adult sheep were subjected to permanent occlusion of the MCA. After a baseline PET scan 2 hours after MCA occlusion, NO inhalation was initiated (2 hours after MCA occlusion); CBF was then quantified repeatedly during and after iNO by [ 15 O]H 2 O PET. To investigate whether the observed iNO effect was confined to the ischemic penumbra, the penumbra was identified by absolute CBF measurements (8 -22 mL/100 gϫ min; Figure 7A , pink). The iNO selectively increased CBF in the ischemic penumbra as compared to the condition before iNO application and as compared to a control animal not receiving NO (encircled; Figure 7A , Ϫ10 minutes, 55 minutes). Quantification of penumbral CBF before and after iNO showed that the penumbral volume decreases significantly by approximately 50% but remains unchanged in control animals (PϽ0.05 vs baseline and vs control; Figure 7C ). These findings substantiate the view that inhalation of NO causes selective vasodilatation of vessels in lowly perfused brain tissue. Met-hemoglobin levels were Ͻ1.3% of total hemoglobin in all animals. 
Potential Side Effects of iNO
A reduction of systemic blood pressure attributable to release of NO in peripheral resistance vessels and an increase in bleeding complications are the major concerns regarding possible systemic side effects of iNO as a stroke therapeutic. In mice, iNO did not exert any effects on blood pressure (Online Table I ) or primary hemostasis. Tail bleeding time showed no difference between iNO-treated and control animals (data not shown).
Discussion
Our experiments demonstrate that iNO is delivered to pial microvessels in a bioactive form, dilates cerebral resistance vessels selectively in hypoperfused tissue, and, thus, improves collateral blood flow to areas in need. Therefore, iNO improves metabolic function and prevents the death of the ischemic penumbra under conditions of transient or permanent reduction of CBF. Therefore, iNO may represent a novel treatment for ischemic conditions in which collateral blood flow is critical for tissue survival, eg, after myocardial or, as shown here, in cerebral ischemia.
Previously, the vascular action of iNO was considered to be confined to the lung. However, recent data suggest that it extends beyond the pulmonary circulation. The iNO has been shown to exert anti-inflammatory effects in mesenteric microvessels, 20 to increase forearm, renal, and myocardial blood flow, [21] [22] [23] and to increase the concentration of cyclic guanosine monophosphate in the aortic wall. 24 These phenomena were attributed to the formation of bioactive NO carriers in the lung that circulate in blood and release NO in extrapulmonary blood vessels. The nature of the NO carriers formed during NO inhalation is still undergoing debate and may involve nitrite, 25, 26 S-nitroso hemoglobin, [27] [28] [29] [30] or other S-nitrosothiols (eg, of cysteine or glutathione), 27, 30 which, among others, may be formed when NO reacts with oxygen to form N 2 O 3 . 31, 32 Consistent with this concept, previous studies using iNO or inhaled ethyl nitrite have shown protection in experimental paradigms in which vasoconstriction plays an important pathophysiological role, eg, experimental subarachnoid hemorrhage. 33, 34 The observed increase in both S-nitroso-hemoglobin and nitrite in the current study and in other studies using NO arterioles (B) in the ischemic penumbra of mice subjected to focal cerebral ischemia by middle cerebral artery occlusion (MCAo). Inhalation of 50 ppm NO increased diameters of both arterioles and venules as compared to baseline values before inhaled NO (iNO; *PϽ0.05, †PϽ0.01; nϭ5 each). C, Regional cerebral blood flow (rCBF) in normal brain, the ischemic core, and the ischemic penumbra during inhalation of 50 ppm NO. The iNO increased blood flow selectively in the ischemic penumbra ( †PϽ0.01 vs normal brain; nϭ5-10 each). D, 18 F-fluorodeoxyglucose micropositron emission tomography (PET) and computed tomography (CT) analysis of glucose metabolism in ischemic brain of control mice (MCAo) and in animals ventilated with 50 ppm NO (MCAo ϩ iNO). The area of reduced glucose uptake is smaller, indicating restoration of cerebral glucose metabolism in NO-treated animals. E, Quantification of 18 F-fluorodeoxyglucose activity reveals higher glucose (normalized to the activity within contralateral hemisphere; regions of interest marked in the inset in green) in the penumbra of NO-treated animals as compared to controls indicating restoration of glucose metabolism after iNO (*PϽ0.05 vs control animals; nϭ5 each).
inhalation 35 suggests that either of these intermediates alone or together may contribute to the reported neuroprotective effect of iNO. However, given the complex nature of the methodology used to measure NO and NO adducts, 36 further studies are needed to elucidate which specific compound mediates the observed cerebrovascular effect of iNO, specifically under physiological conditions/normoxia in which nitrite concentrations in the range of the plasma levels observed in the present study did not result in detectable increases in total forearm blood flow or volume. 37, 38 Both molecules measured in the current study have been proposed to release NO in response to local oxygen partial pressure (PO 2 ) gradients, either by an allosteric regulation 39 or by an oxygenation-dependent enzymatic function of hemoglobin as a nitrite reductase. 40 Also, a pathway in which nitrite is the source for S-nitroso-hemoglobin has been proposed. 41, 42 The specific role of hemoglobin versus nitrite as NO carriers has been discussed in various studies and the relevance of one over the other is still undergoing dis-pute. [43] [44] [45] Yet, there is common agreement that circulating blood can transport NO bioactivity (as also evidenced by the current study) and release NO during the conformational transition of hemoglobin from the oxygenated R-state to the deoxygenated T-state.
Under physiological conditions, hemoglobin deoxygenates predominantly in capillaries and venules. 12 Hence, as demonstrated by the current results, release of NO occurs specifically at these sites and causes exclusive dilatation of venules, whereas arterioles remain unaffected. Accordingly, iNO should not have any effect on systemic blood pressure and tissue perfusion. This is supported by the current results in mice showing no effect of iNO on normal blood pressure and on CBF in normally perfused brain and by studies in humans showing that iNO at clinically relevant concentrations (Ͻ50 ppm) may have a minor but not significant effect on systemic blood pressure. 46, 47 Under conditions of reduced tissue perfusion, however, iNO not only dilates venules but also has a marked vasodi- latatory effect on cerebral arterioles. The mechanism hypothesized to be responsible for this observation is a shift of NO release from the venular toward the arteriolar side of the microvasculature; in vivo, NO imaging demonstrating arteriolar NO only after hypoperfusion supports this notion. Arteriolar release of NO under compromised blood flow conditions is most likely attributable to the shift of hemoglobin deoxygenation toward the arteriolar compartment, a phenomenon well-known to occur in the microvasculature during hypoxia, ischemia, or anemia. 48, 49 The intriguing fact about the shift of NO release toward the arteriolar side is that NO-induced dilatation of arterioles, the major resistance vessels in the circulatory system, results in an increase of blood flow specifically in areas suffering from hypoxia or ischemia. Accordingly, NO administered by inhalation exerts the properties of an ideal vasodilator: no significant effect on hemodynamics in normally perfused tissue (no effect on systemic blood pressure or blood flow in normal brain), whereas blood flow is exclusively increased in hypoxic-ischemic tissue. This property of iNO was proven in experimental stroke in mice and sheep; iNO exclusively dilated cerebral arterioles in the ischemic penumbra, thereby selectively increasing CBF in this critically underperfused area of the brain, whereas blood flow was not altered in the surrounding normal cortex. Hence, iNO caused an inverse steal phenomenon, known as Robin Hood effect, 50 which resulted in enhanced glucose metabolism and long-term survival of penumbral brain tissue otherwise doomed to die by ischemia. It is important to consider that although the observed increase in CBF in the ischemic penumbra may seem modest in absolute values, there is ample evidence in the literature that tissue perfusion is not linearly related to neurological outcome; enhancement of perfusion to modest levels above the penumbral threshold as observed by laser Doppler flowmetry therefore can significantly improve tissue viability and survival (as evidenced by FGD-PET in mice) and, thus, neurological outcome.
In addition to the selective increase of CBF, the neuroprotective effect of iNO also may be mediated by reduced inflammatory response. 20, 51 However, we could not confirm this mechanism for cerebral ischemia because leukocyte infiltration was not altered by iNO in the current experiment (Online Figure IV) .
Various experimental studies have previously demonstrated the beneficial effect of NO derivates for the treatment of ischemic stroke. Infusion of the NO precursor L-arginine or NO donors were shown to increase CBF after experimental stroke 52, 53 ; however, so far, none of these promising approaches could be translated into the clinic because of various reasons. 54 Some approaches impaired the endogenous NO production, 55 whereas others lacked a clinically feasible mode of administration 56 or, most importantly, caused significant reduction of systemic blood pressure, eg, L-arginine infusion. 57 As compared to previous attempts that tried to utilize NO-based strategies for the treatment of tissue ischemia, the main advantages of iNO are its specific effect on hypoperfused tissue without any effect on systemic blood pressure, its immediate action, simple and well-investigated route of administration, its efficacy across species, and its excellent safety profile that is based on the use of iNO in several thousand patients with pulmonary disorders. Because of these properties iNO may be readily implemented into primary care and serve as an ideal stroke therapy until interventional or spontaneous reperfusion occurs. Because currently Ͻ5% of stroke patients receive thrombolysis by rtPA, iNO is likely to have a significant clinical impact.
Despite these positive properties that suggest iNO as an almost ideal stroke therapeutic, several points need to be carefully addressed before a clinical study can be initiated. One of the most important points is certainly the potential effect of iNO on bleeding time. It has been proposed that high concentrations of iNO may affect hemostasis and thus may result in bleeding complications. We addressed this important issue in the current study but did not detect any indication that at the applied dose of 50 ppm, iNO may prolong bleeding time. This finding is supported by anecdotal data about the safe use of iNO during lung 58 and brain surgery, 59 and by several clinical studies that did not report increased bleeding complications after iNO in patients. 60, 61 Nevertheless, this issue needs to be addressed carefully before a clinical study can be initiated.
Taken together, our experiments suggest that iNO exerts the properties of an ideal therapeutic agent for cerebral ischemia. The iNO has no hemodynamic effects on normally perfused tissue but increases blood flow selectively in ischemic tissue. Because iNO is already approved for use in humans, its clinical evaluation for ischemic conditions in which collateral blood flow is important, eg, ischemic stroke or myocardial infarction, may be possible in the near future.
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Figure 7. Nitric oxide (NO) inhalation after ischemic stroke improves penumbral perfusion in sheep.
A, Serial H 2 O positron emission tomography (PET) imaging reveals that inhaled NO (iNO; 50 ppm) increases cerebral blood flow in the ischemic penumbra (encircled), whereas penumbral blood flow remains unchanged in control animals. Of note, the anatomic location of the penumbra in this model of distal middle cerebral artery (MCA) occlusion is different than that in mice (proximal occlusion, see Figures 4D and 5A, infarct core in the striatum, penumbra spreads toward the cortex). In sheep, the infarct core is located in the cortex, whereas the penumbra surrounds the core and spreads toward the striatum. B, Quantification of normally perfused, ischemic, and penumbral tissue volumes reveals that penumbral volume decreases significantly during NO inhalation (nϭ3 per group; *PϽ0.05 vs control and vs baseline PET at tϭϪ10 min), whereas infarct core volume does not increase (yellow).
